- Home
- CYN vs BGLC Comparison
CYN vs BGLC Comparison
Compare CYN & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | BGLC |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 10.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CYN | BGLC |
|---|---|---|
| Price | $2.24 | $3.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 268.7K | 9.1K |
| Earning Date | 03-04-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $457,227.00 | ★ $9,465,006.00 |
| Revenue This Year | $31.96 | N/A |
| Revenue Next Year | $1,459.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 347.74 | 2.21 |
| 52 Week Low | $2.10 | $2.01 |
| 52 Week High | $85.55 | $15.60 |
Technical Indicators
Market Signals| Indicator | CYN | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 33.93 | 22.37 |
| Support Level | $2.18 | $3.69 |
| Resistance Level | $2.78 | $3.89 |
| Average True Range (ATR) | 0.21 | 0.20 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 15.91 | 1.63 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About BGLC BioNexus Gene Lab Corp
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.